Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $42. The company’s shares closed yesterday at $19.73, close to its 52-week low of $17.16.
“We account for Cervical Dystonia (assigned 90% PoS) and Plantar Fasciitis (applied 20% PoS) in our model.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.7% and a 45.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $44.33.
Based on Revance Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.83 million. In comparison, last year the company had a GAAP net loss of $35.91 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.